Corticotropin Stimulation in Adrenal Venous Sampling for Patients With Primary Aldosteronism: The ADOPA Randomized Clinical Trial

What Was Tested

This randomized controlled trial paper looks at ACTH (Corticotropin).

To evaluate whether treatment decisions based on AVS with or without ACTH stimulation lead to different biochemical and clinical remission rates in patients with PA.

Why It Was Studied

Adrenal venous sampling (AVS) is usually recommended to distinguish between unilateral and bilateral primary aldosteronism (PA) before definitive surgical or medical treatment is offered.

Whether a treatment decision based on AVS with or without corticotropin (ACTH) stimulation leads to different biochemical and clinical remission rates in patients with PA remains unclear.

Who Took Part

The abstract describes 2023, patients taking part.

By PubMed's age tags, the people studied were teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

This randomized clinical trial (RCT) was conducted at a tertiary hospital in China from July 8, 2020, to February 20, 2023, among patients with PA aged 18 to 70 years.

Patients were followed up for 12 months after the initiation of treatment.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got ACTH (Corticotropin) and who got the comparison, which limits bias.

A time span of 12 months appears in the methods.

An intention-to-diagnose analysis was conducted.

Patients were randomly assigned to undergo either ACTH-stimulated or non-ACTH-stimulated AVS.

What Was Measured

Adrenal venous sampling (AVS) is usually recommended to distinguish between unilateral and bilateral primary aldosteronism (PA) before definitive surgical or medical treatment is offered.

Topics PubMed links to this paper include Adrenal Glands, Adrenalectomy, Adrenocorticotropic Hormone and Hyperaldosteronism.

What This Means in Plain Language

The paper is a randomized study of ACTH (Corticotropin) in 2023, patients over 12 months.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (JAMA network open), a journal based in United States.

More context: the ACTH (Corticotropin) compound page, all human trials.